Insights into Metabolite Diagnostic Biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Yamano, Emi, Watanabe, Yasuyoshi, Kataoka, Yosky · International journal of molecular sciences · 2021 · DOI
Quick Summary
ME/CFS is a serious condition that causes extreme exhaustion and is difficult to diagnose because we don't have reliable tests for it. This review examined research on how the chemicals in patients' bodies differ from healthy people, looking for patterns that could help doctors identify ME/CFS with a simple blood test. Scientists reviewed studies that measured these body chemicals and tested them in animal models to understand what goes wrong in ME/CFS.
Why It Matters
Many ME/CFS patients struggle for years without diagnosis because no objective test exists; identifying reliable metabolic biomarkers could enable faster, more accurate diagnosis and guide development of targeted treatments. This review consolidates emerging metabolomic evidence that may accelerate the pathway from laboratory findings to clinical diagnostic tools that patients urgently need.
Observed Findings
Metabolomic analysis methods are increasingly used to identify biochemical differences between ME/CFS patients and healthy controls
Multiple metabolite classes show alterations in ME/CFS patients, suggesting multi-system metabolic dysfunction
Animal models of ME/CFS demonstrate measurable metabolic signatures that partially parallel human findings
Current research has not yet produced a single validated diagnostic biomarker for clinical implementation
Heterogeneity in study designs and methods limits direct comparison across ME/CFS metabolomic research
Inferred Conclusions
Metabolomic approaches hold promise for identifying objective biomarkers for ME/CFS diagnosis and understanding disease mechanisms
Systematic standardization of metabolomic protocols and larger validation studies are necessary before clinical translation
Integration of findings from human patient studies and animal models can strengthen the evidence base for biomarker development
Remaining Questions
Which specific metabolite(s) or metabolite panels show sufficient diagnostic sensitivity and specificity for clinical use?
How do metabolic signatures change over disease course and in response to potential treatments?
What This Study Does Not Prove
This review does not establish that any specific metabolite biomarker is ready for clinical use—it summarizes emerging evidence rather than providing definitive diagnostic validation. The findings represent correlations between metabolic changes and ME/CFS status but do not necessarily prove these metabolites cause the disease. Results from animal models may not directly translate to human patients due to differences in disease pathogenesis and study conditions.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.